J&J agrees to Propulsid settlement

A Johnson & Johnson Propulsid litigation settlement will become effective once 85% of the death claims agree to its terms, J&J's Janssen division announced Feb. 5. J&J will pay between $69.5 mil. and $90 mil., depending on how many plaintiffs enroll in the program. The federal multi-district litigation includes approximately 4,000 plaintiffs, 300 of whom are alleged to have died from use of the drug. J&J ceased marketing Propulsid (cisapride) in 2000; the gastrointestinal agent is currently available through a limited access program...